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Abstract: Chemotherapy-induced nausea and vomiting (CINV) are among the most feared 
and distressing symptoms experienced by patients with cancer. The knowledge of the patho-
genesis and neuropharmacology of CINV has expanded enormously over the last decades, the 
most significant discoveries being the role of 5-hydroxytryptamine (5-HT)3- and neurokinin 
(NK)1 receptors in the emetic reflex arch. This has led to the development of two new classes 
of antiemetics acting as highly selective antagonists at one of these receptors. These drugs 
have had a huge impact in the protection from chemotherapy-induced vomiting, whereas the 
effect on nausea seems to be limited. The first NK1 receptor antagonist, aprepitant, became 
clinically available in 2003, and casopitant, the second in this class of antiemetics, has now 
completed phase III trials. This review delineates the properties and clinical use of casopitant 
in the prevention of CINV.
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Introduction
Historically, chemotherapy-induced nausea and vomiting (CINV) are among the most 
feared and distressing symptoms experienced by patients with cancer.1 Patients’ ranking 
of side effects have changed over time. In a work by Coates and colleagues in 1983, 
patients receiving cancer chemotherapy reported vomiting and nausea as the two most 
severe side effects.1 In another work ten years later, the same group found that patients 
experienced nausea as the most severe side effect of chemotherapy, and vomiting was 
now ranked fifth.2 With the introduction of high-dose metoclopramide in 1981 the 
antiemetic outcome markedly changed, providing significant reduction in cisplatin-
induced emesis.3 In the 1980s a new class of antiemetic agents, the 5-hydroxytryptamine 
(5-HT)3 receptor antagonists, were developed and became clinically available in the 
early 1990s. This further improved protection from emesis, and the efficacy was 
potentiated by addition of dexamethasone.4 Patients perception of side-effects in 1993 
emphasises, that the 5-HT3-receptor antagonists are more preventive of vomiting 
than nausea, and in particular management of delayed nausea and vomiting remains 
a challenge.5 The latest approach towards elimination of CINV was made with the 
appearance of the neurokinin (NK)1 receptor antagonists. When added to the standard 
antiemetic regimen until 2004 (a 5-HT3-receptor antagonist and a corticosteroid), the 
NK1 receptor antagonist, aprepitant, significantly improved the percentage of patients 
with complete response (CR), defined as no emetic episodes and no rescue therapy on 
days 1 to 5 after the initiation of chemotherapy. Even a significant reduction in delayed 
emesis was demonstrated.6–9 In 2003, the first NK1 receptor antagonist, aprepitant, Therapeutics and Clinical Risk Management 2009:5 376
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became commercially available. The second drug in this 
class, casopitant (casopitant mesylate), has now completed 
phase II and phase III trials, demonstrating efficacy in 
the same magnitude as demonstrated with aprepitant. 
Previous indications for casopitant, overactive bladder, social 
anxiety disorder, major depressive disorder, insomnia, and 
fibromyalgia have been revoked, and remaining indications 
are CINV and postoperative nausea and vomiting (PONV). 
This review delineates the properties and clinical use of 
casopitant in the prevention of chemotherapy-induced nausea 
and vomiting. It should be noted, that most of the clinical 
data is availably in abstract form only.
Neuropharmacology of emesis
Insight in the complex human emetic pathway has been 
achieved primarily on the basis of animal models.10 It is a 
general assumption, that the vomiting centre (VC) in the 
medulla oblongata, the chemoreceptor trigger zone (CTZ) 
in the area postrema (AP) on the caudal margin of the IVth 
ventricle, the visceral afferent neurons and abdominal vagal 
afferent neurons, form the central emetic pathway.11 The 
VC is representing anatomical structures at the level of the 
nucleus tractus solitarius (NTS) and the visceral and somatic 
motor nuclei. Another acceptation is that CINV results from 
directly activation of the NTS by visceral afferent neurons 
and/or by inputs from the CTZ. The CTZ, in turn, may 
be stimulated by abdominal vagal afferent activation by 
release of serotonin (5-HT3) from the enterochromaffin cells 
(EC cells) in the gut. The reflex activation of the NTS and the 
CTZ further extends to the visceral and somatic motor nuclei 
giving rise to physiological changes, resulting in nausea and 
vomiting.12 Radioligand binding studies have identified the 
binding affinity of several neurotransmitters to receptors 
such as dopamine (D2), muscarine cholinergic, histamine 
(H1) and serotonin (5-HT3), involved in the emetic response 
to chemotherapy.10 The fundamental role for serotonin and 
5-HT3
_receptors in the emetic pathway was discovered in 
the mid 1980s, giving rise to the development of 5-HT3- 
receptor antagonists.13 Recently, the role of substance P and 
the neurokinin1 (NK1) receptors in the emetic pathway has 
been investigated, resulting in development of the NK1 
receptor antagonists.
Substance P and NK1 receptor 
antagonists
Substance P (SP) was isolated in 1931 but not purified and 
sequenced until 1970.14,15 SP is a member of a family of small 
peptides, the mammalian tackykinins (TKs).16 Three receptors 
for TKs (NK1, NK2, and NK3) have been cloned, with SP 
being the preferred agonist at NK1 receptors.16 The role 
of SP in emesis dates back to 1984, when Carpenter and 
colleauges demonstrated that systemic administration of 
the neuropeptide caused emesis in dogs.17 In 1993, Andrews 
and Bhandari suggested that resinferatoxin exerts its potent 
antiemetic activity by depleting SP at a central site in the 
emetic pathway, possibly in the NTS.18 Penetration of the 
blood-brain barrier is essential for the antiemetic activity 
of systemically administered NK1 receptor antagonists, a 
quality that the peptide-based NK1 receptor antagonists did 
not exhibit.19,20 Hence a milestone was reached, when the first 
nonpeptide NK1 receptor antagonist, CP-96,345, with high 
affinity for the NK1 receptor, was developed in 1991.21 This 
finding was followed by a number of experimental studies 
confirming a broad-spectrum antiemetic activity of non-
peptide NK1 receptor antagonists.22–25 These studies led to 
the development of the latest class of antiemetic agents, with 
aprepitant being the first clinically available NK1 receptor 
antagonist. Casopitant has now completed phase III trials 
for the prevention of CINV from moderately and highly 
emetogenic chemotherapy.
Metabolism, pharmacokinetics,  
and interactions
Preclinical studies
Only sparse information about the ADME (absorption, 
distribution, metabolism, and excretion) properties of caso-
pitant (oral and intravenous formulation) has been published. 
Casopitant is a piperazine derivative [1-piperidinecarboxamide, 
4-(4-acetyl-1-piperazinyl)-N-((1R)-1(3,5-bis(trifluorometh
yl)phenyl)-ethyl)-2-(4-fluoro-2-methylphenyl-N-methyl- 
(2R,4S)-; GW679769] (Figure 1).26 In a ferret-model of cis-
platin-induced emesis, GW679769 (casopitant) inhibited 
retching and vomiting and reduced nausea-like behaviours 
in a dose-dependent manner.27–29 Several clinical trials have 
assessed safety, potential interactions and pharmacokinetic 
properties of casopitant; however many data is available in 
abstract form only.
The pharmacokinetics and brain penetration of casopi-
tant were studied in the ferret-model of cisplatin-induced 
emesis. Following a single intraperitoneal dose, radioactive 
labeled casopitant ([14C] casopitant) was rapidly absorbed, 
with plasma and brain concentrations being approximately 
equal at two hours post-dosing. [14C] casopitant was found 
in the brain as the parent compound and two major oxidative 
metabolites (M1 and M2), accounting for approximately Therapeutics and Clinical Risk Management 2009:5 377
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76%, 19%, and 3% of the radioactivity, respectively; 
suggesting that the pharmacologic activity of casopitant in 
the ferret is largely attributable to the parent compound.26 
An in vitro receptor binding affinity study describes, that 
casopitant possesses a high affinity for brain NK1 receptors 
in the ferret.26
Because casopitant is intended to be administered in 
combination with a 5-HT3-receptor antagonist and because 
therapeutic synergy has been observed with this combina-
tion in the ferret, a drug interaction study was conducted.28 
Following co-administration of ondansetron and casopitant 
in ferrets, no alteration of disposition of either agent was 
seen. A synergistic antiemetic activity was demonstrated, 
proposing complementary mechanisms of pharmacologic 
actions of the two agents.30 No information about animal 
toxicity was described in the studies above.
Clinical studies
Pharmacokinetic and pharmacodynamic aspects (PK/PD) 
of casopitant were assessed in two phase II trials (2802 PK 
samples from 765 subjects) in patients undergoing treatment 
with moderately and highly emetogenic chemotherapy (MEC 
and HEC). In addition to ondansetron and dexamethasone, 
patients received placebo; 50-, 100-, or 150 mg daily of oral 
casopitant for three days; or a single oral dose of 150 mg 
casopitant, starting prior to chemotherapy on day 1. The dis-
tribution of casopitant follows a two-compartment first-order 
model, and the oral absorption was in general rapid, however 
30% of subjects exhibited delayed and slow oral absorp-
tion. Oral clearance was 17.4 L/h/70 kg, displaying a large 
intersubject variability (72%). Body weight was identified 
as a significant covariate of casopitant clearance and central 
volume of distribution. Further, it was shown that low 
casopitant area under the curve (AUC) in patients receiving 
HEC increased the risk of emesis in some patients, suggesting 
that high concentrations of casopitant during the first 24 h 
may be important for adequate pharmacological response. 
Oral casopitant administered as a single dose of 150 mg on 
day 1, or followed by 50 mg doses on days 2 and 3, seem 
to provide adequate receptor occupancy and prevention of 
CINV associated with MEC and HEC.31
A PK/PD study analyzed data (1637 PK samples from 
562 subjects) from a phase II trial in which casopitant was 
evaluated for the prevention of PONV. Patients were female 
and undergoing surgery and at high risk for PONV. In addi-
tion to ondansetron, patients received placebo; 50, 100, or 
150 mg single oral doses of casopitant prior to surgery. In 
this study oral clearance was 24.4 L/h/70kg, displaying 
moderate intersubject variability (48%). Body-weight was 
also identified as a significant covariate of casopitant central 
volume of distribution, but not of clearance. For the treatment 
of PONV in high-risk patients, a dose of 50 mg casopitant is 
suggested to be the minimally effective dose.32
Casopitant is a substrate and weak-to-moderate 
inhibitor of CYP3A4.33 Based on the role of CYP3A4 in 
the metabolism of several antiemetic drugs, pharmaco-
kinetic interactions between casopitant, dexamethasone 
(substrate and inducer of CYP3A4) and ondansetron (mixed 
CYP substrate) were assessed in a two-part, three-period, 
single-sequence phase I study in 44 healthy adult subjects. 
The study aimed at investigating possible changes in bio-
availability of casopitant, ondansetron and dexamethasone, 
when these agents are co-administered. In Part 1, which was 
representative of a three-day regimen for the prevention of 
CINV resulting from HEC, subjects received oral casopi-
tant (150 mg, day 1; 50 mg, days 2–3) in regimen A; oral 
dexamethasone (20 mg, day 1; 8 mg twice daily, days 2–3) 
and IV ondansetron (32 mg, day 1) in regimen B; and oral 
casopitant (150 mg, day 1; 50 mg, days 2–3), a reduced 
dose of oral dexamethasone (12 mg, day 1; 8 mg once daily, 
days 2–3), and IV ondansetron (32 mg, day 1) in regimen C. 
In Part 2, which was representative of a three-day regimen 
for the prevention of CINV resulting from MEC, subjects 
received oral casopitant (150 mg, day 1; 50 mg, days 2–3) in 
regimen D; IV dexamethasone (8 mg, day 1; 8 mg twice daily, 
days 2–3) and oral ondansetron (8 mg twice daily, day 1) 
in regimen E; and oral casopitant (150 mg, day 1; 50 mg, 
days 2–3), IV dexamethasone (8 mg, day 1; 8 mg twice daily, 
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in regimen F. Blood samples for PK analysis were collected 
at fixed times. The pharmacokinetic results of the Part 2 
regimens demonstrated a 28% increase in mean casopitant 
AUC on day 1, when casopitant was co-administered with 
12 mg oral dexamethasone and 32 mg ondansetron compared 
to casopitant administered alone. Further, it was shown that 
on Day 1, the lower dose of dexamethasone (12 mg) as 
used in regimen C resulted in a lower mean dexamethasone 
AUC and maximum concentration (Cmax), by 17% and 35%, 
respectively, when compared to dose regimen B (20 mg 
of dexamethasone). Dose normalization of the pharmaco-
kinetic parameters showed that casopitant increased the 
AUC of oral dexamethasone by 39%. After three days of 
co-administration, AUC resulting from 8 mg once daily of 
oral dexamethasone combined with 50 mg oral casopitant 
was similar to that resulting from 8 mg twice daily of oral 
dexamethasone alone. Plasma exposures of 32 mg ondanse-
tron were not affected by co-administration with casopitant. 
The results of Part 2 showed a 16% increase in mean caso-
pitant AUC on day 1, when casopitant was co-administered 
with 8 mg oral dexamethasone and 8 mg ondansetron twice 
daily, compared to casopitant administered alone. As to dexa-
methasone an increase in AUC day 1 by 21% was observed 
when dexamethasone (8 mg) was co-administrered with 
150 mg casopitant and 8 mg ondansetron twice daily. The 
pharmacokinetics of ondansetron in Part 2 was not altered 
by co-administration with casopitant. All dose regimens 
were generally well tolerated, with headache and dizziness 
being the most commonly reported adverse events (AEs). In 
conclusion, the study suggests a reduction in dexamethasone 
dose of 40%–50%, when repeat-dose oral dexamethasone is 
to be co-administered with oral casopitant, whereas there is 
no need to change the dose of ondansetron or casopitant.34
In another phase I, two-part, two-period study, the effect 
of casopitant on the pharmacokinetics of two 5-HT3-RAs, 
dolasetron and granisetron, was investigated. Dolasetron 
is reduced to its active metabolite, hydrodolasetron, which 
is metabolized by CYP2D6 with minor involvement of 
CYP3A4. Plasma exposures of hydro-dolasetron are usually 
increased approximately threefold in CYP2D6 poor metabo-
lizers (PMs) as compared to extensive metabolizers (EMs). 
For CYP2D6 PMs, CYP3A4 is likely to play a larger role in 
the clearance of hydrodolasetron, and these subjects may be 
more sensitive to co-administration of inhibitors of CYP3A4, 
such as casopitant. Granisetron is primarily metabolized 
by CYP3A4 with a minor contribution from CYP1A1. A total 
of 18 subjects, (nine were CYP2D6 EMs and nine were 
CYP2D6 PMs), received oral dolasetron 100 mg days 1–3 
(period 1), and 5–14 days later the same dose of dolasetron 
combined with oral casopitant 150 mg day 1, and 50 mg days 
2–3 (period 2). The granisetron cohort (19 subjects) received 
oral granisetron 2 mg days 1–3 (period 1), and 5–14 days 
later combined with oral casopitant 150 mg day 1, and 50 mg 
days 2–3 (period 2). Blood samples for PK analysis were 
collected at fixed times. The largest changes in hydrodolas-
etron exposure after coadministration with casopitant were 
seen in CYP2D6 EMs, with a 24% increase in hydrodolas-
etron AUC on day 1 and 30% increase in Cmax on days 1 and 3. 
All other changes in hydrodolasetron exposure were 20%, 
and granisetron exposure was not altered to any relevant 
extent (11%). None of the changes observed are considered 
clinically meaningful. Coadministration of casopitant with 
dolasetron or granisetron was well tolerated.33
In a phase I trial, the effect of casopitant on the PK and PD 
of steady-state warfarin in healthy adults was studied. In vitro 
studies had shown that casopitant is a dose and duration-
dependent inhibitor of CYP3A4, and a moderate inducer of 
CYP2C9. These enzymes are important in the metabolism of 
warfarin. Subjects received warfarin and were randomized 
to receive either casopitant, 150 mg day 1, 50 mg days 2 and 
3, and warfarin, days 1–10, or casopitant, 60 mg daily, and 
warfarin, days 1–14. When casopitant was administered for 
three days, there was no significant alteration in steady-state 
Cmax and AUC of R- and S-warfarin. In the other regimen 
R- and S-warfarin AUC was increased 1.31- and 1.27-fold, 
respectively. However, steady-state international normal-
ized ratio (INR) was not significantly affected with either 
regimen.35
A number of other studies have addressed the role of 
CYP-enzymes and drug-interactions with casopitant. These 
studies enrolled a limited number of patients, but it seems 
likely that casopitant can be administered safely with drugs 
metabolized by CYP3A4, such as cyclophosphamide and 
docetaxel.36,37 Vinorelbine and etoposide, (likely to be 
co-administered with cisplatin), are metabolized by CYP3A, 
potentially leading to increased plasma levels of these agents 
when co-administered with casopitant. Oral contraceptives 
are also metabolized by CYP3A-enzymes. Co-administration 
of casopitant and oral contraceptives may result in lower 
levels of the hormones, causing the oral contraceptives to be 
an uncertain method of contraception when co-administred 
with casopitant. No data on these potential interaction risks 
have been published.
Ketoconazole is a strong CYP3A4 inhibitor. A phase I 
study characterized the effect of ketoconazole on the PK 
of casopitant, demonstrating a four- to six-fold increase Therapeutics and Clinical Risk Management 2009:5 379
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in casopitant exposure. However no safety concerns were 
noted.38 Yet another phase I study was conducted to investi-
gate the potential of casopitant to prolong the QTc interval 
in supratherapeutic doses and when combined with keto-
conazole. Compared with placebo, no significant impact on 
QTc was observed.39
No available data has been published as concerns; oral 
absorption fraction, influence of concomitant food consump-
tion, half-life, or percentage of NK1 receptor occupancy 
needed for optimal efficacy of casopitant.
Clinical development
The clinical development of casopitant in preventing CINV 
comprises phase I, phase II, and phase III trials. In the section 
above phase I trials were described. Phase II and phase III 
trials handle documentation for casopitant in the prevention 
of CINV in patients receiving MEC and HEC, respectively.
Phase ii trials
Patients treated with MeC
A large phase II, multicenter, randomized, double-blind, 
placebo-controlled, dose-ranging, parallel group trial, 
evaluated the addition of casopitant to standard prophy-
laxis (ondansetron plus dexamethasone) in patients receiv-
ing MEC.40 Primary endpoints were rates of complete 
response (CR), defined as no vomiting or retching, no 
use of rescue antiemetics and no premature withdrawal 
during the first 120 hours after initiation of MEC; and no 
significant nausea (SN), during the first 120 hours after 
initiation of MEC. The MEC regimens used were: cyclo-
phosphamide (500–1500 mg/m2) with another unspecified 
MEC; cyclophosphamide (750–1500 mg/m2) alone; oxali-
platin (85 mg/m2); doxorubicin (60 mg/m2); epirubicin 
(90 mg/m2); or carboplatin AUC  5. Patients were strati-
fied by gender and taxane use. 719 patients were randomized 
to six arms; arms 5 and 6 being exploratory. In addition to 
ondansetron 8 mg twice-daily day 1–3 and dexamethasone 
8 mg IV day 1, Patients in arms 1–5 received either placebo, 
casopitant 50 mg daily days 1–3, casopitant 100 mg daily days 
1–3, casopitant 150 mg daily days 1–3, or casopitant 150 mg 
day 1. Patients in arm 6 received ondansetron 16 mg daily 
days 1–3, dexamethasone 8 mg day 1 and casopitant 150 mg 
daily days 1–3. CR (120 h) was achieved in 81% of patients 
receiving 50 mg casopitant, compared to 70% in the control 
arm (p = 0.0410). CR (120 h) rates for the 100 mg and 150 mg 
casopitant arms were 79% and 85%, respectively (p = 0.1092, 
0.0124). There were no significant differences among groups 
in the rates of CR (24 h) or no SN. The exploratory arm 5, 
casopitant 150 mg day 1, was of particular interest, with CR 
(120 h) rate and no SN rate of 80% and 66%, respectively, 
in arm 6 the figures were 84% and 70%. The antiemetic 
regimens were well tolerated, with nausea, fatigue and neutro-
penia being the most common side effects.40
A subgroup analysis from the phase II trial examined the 
antiemetic efficacy in patients (n = 124) with gastrointestinal 
cancers receiving oxaliplatin 85 mg/m2. The majority were 
diagnosed with colorectal cancer (90%). CR was achieved 
in 83%, 76%, and 86% in the three casopitant arms (50 mg, 
100 mg, and 150 mg, respectively), compared to 61% in the 
control arm. Although one should be cautious with interpre-
tation of data of a small subgroup analysis, CR rates were 
similar with those of the complete dataset.41
Safety and efficacy of casopitant in women with breast 
cancer, was considered in another subgroup analysis 
of the phase II trial. Patients (n = 176) received one or 
more of the following regimens: cyclophosphamide (C) 
(500–1500 mg/m2) with another unspecified MEC; cyclo-
phosphamide (750–1500 mg/m2) alone or with another 
minimally emetogenic agent; doxorubicin (A) (60 mg/m2); 
or epirubicin (E) (90 mg/m2). The majority received a 
combination of AC or EC (n = 102) or a taxane (n = 37). 
This subgroup analysis found that CR rates were similar 
to the overall response profile. The antiemetic regimens 
were generally well tolerated. Nausea (24%), alopecia 
(17%), neutropenia (16%), anorexia (13%), and fatigue 
(12%), were the most commonly reported side effects in 
this patient group.42
Patients treated with HeC
Another phase II trial examined the antiemetic efficacy of 
casopitant in addition to standard antiemetic prophylaxis 
in patients receiving cisplatin (70 mg/m2) day 1.43 It was 
conducted as a multicenter, randomized, double-blind, 
placebo-controlled, dose-ranging, parallel group study. 
Patients (n = 493) were stratified by gender and randomized 
among six arms. All patients received ondansetron 32 mg 
IV day 1 and dexamethasone PO day 1–4. The casopitant 
doses in arms 2, 3, and 4 were the same as in the phase II, MEC 
study (50 mg, 100 mg, and 150 mg daily days 1–3) and com-
pared to placebo in arm 1. Arms 5 and 6 were exploratory with 
casopitant 150 mg day 1 and aprepitant (125 mg day 1 and 
80 mg day 2–3), respectively. As in the MEC study, results 
demonstrated that casopitant significantly improved the CR 
(120 h) rates. CR (120 h) was achieved in 76% of patients 
receiving 50 mg casopitant compared to 60% in the control 
arm. CR (120 h) rates for the 100 mg and 150 mg casopitant Therapeutics and Clinical Risk Management 2009:5 380
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arms were 86% and 77%, respectively. Again it was revealed 
that casopitant administered as a single dose, 150 mg day 1, 
resulted in a similar high response rate, 75%. The CR (120 h) 
was 72% for the three-day aprepitant regimen. The preven-
tion of emesis in the 24 hours after cisplatin was similar in 
all groups with CR rates in the range of 86%–96%. Again 
the addition of casopitant to standard prophylaxis was well 
tolerated. Neutropenia, nausea and hiccups (17%) were 
the most common side effects reported.43
The phase II studies indicated that a single dose of 
casopitant 150 mg was as good as a three-day regimen. Further-
more no evident dose-efficacy correlation was observed 
(although casopitant 50 mg and 150 mg was superior to 
casopitant 100 mg in the phase II MEC trail, as the latter was 
insignificant). Emergence of the intravenous formulation of 
casopitant and the results from the phase II trials contributed 
to the design of the phase III trials.
Phase iii trials
Patients treated with MeC
The phase III, MEC study was a multinational, double-blind, 
placebo-controlled trial.44,45 Patients (n = 1933, 95% diagnosed 
with breast cancer) received a regimen consisting of an 
anthracycline plus cyclophosphamide (AC). In addition to 
antiemetics in the control arm (dexamethasone 8 mg IV day 1 
and ondansetron 8 mg twice daily PO day 1–3) patients were 
randomized to receive either placebo (control) or one of three 
dosing regimens: casopitant 150 mg PO day 1; casopitant 
150 mg PO day 1 and 50 mg PO day 2–3; or casopitant 
90 mg IV day 1 and 50 mg PO day 2–3 (Table 1). Therapy 
was continued for up to four cycles. The primary endpoint 
was CR rate (120 h), defined as no vomiting or retching, 
no use of rescue antiemetics and no premature withdrawal 
during the first 120 hours after initiation of chemotherapy. All 
casopitant arms were superior to the control arm as concerns 
CR rates. In the group of patients receiving the single oral 
dose of casopitant, CR (120 h) was 73% as compared to 59% 
in controls (p  0.0001 for all treatment arms) in the first 
treatment cycle (Figure 1), and the improvement appeared 
to be maintained through cycles two to four. An improve-
ment was also demonstrated for the secondary endpoint, 
no vomiting. Similar observations were noticed for the 
group receiving casopitant 150 mg PO day 1 and 50 mg PO 
day 2–3, with CR (120 h) at 73%.44 Finally, patients in the 
Table 1 Dose regimens, complete response (CR), and no emesis (ee) of phase ii and phase iii clinical trials in patients receiving MeC 
or HeC
Clinical trial Study arm CR (120) No EE (120)
Phase ii, MeC Control regimen: Ond 8 mg bid D1–3 + Dex 8 mg iv D1 70% NA
Cas 50 mg D1–3 + Control regimen 81% NA
Cas 100 mg D1–3 + Control regimen 79% NA
Cas 150 mg D1–3 + Control regimen 85% NA
Cas 150 mg D1 + Control regimen 80% NA
Cas 150 mg D1–3 + Ond 16 mg D1–3 + Dex 8 mg iv D1 84% NA
Phase ii, HeC Control regimen: Ond 32 mg iv D1 + Dex D1–4 60% NA
Cas 50 mg D1–3 + Control regimen 76% NA
Cas 100 mg D1–3 + Control regimen 86% NA
Cas 150 mg D1–3 + Control regimen 77% NA
Cas 150 mg D1 + Controll regimen 75% NA
Aprep 125 mg D1, 80 mg D2–3 + Control regimen 72% NA
Phase iii, MeC Control regimen: Ond 8 mg bid D1–3 + Dex 8 mg iv D1 59% 63%
Cas 150 mg D1 + Control regimen 73% 80%
Cas 150 mg D1, Cas 50 mg D2–3 + Control regimen 73% 81%
Cas 90 mg iv D1, Cas 50 mg D2–3 + Control regimen 74% 78%
Phase iii, HeC Control regimen: Ond 32 mg iv D1 + Dex 20 mg D1, Dex 8 mg bid D2–4 66% 68%
Cas 150 mg D1 + Control regimen* 86% 89%
  Cas 90 mg iv D1, Cas 50 mg D2–3 + Control regimen** 80% 83%
Notes: *Ond 32 mg iv D1 + Dex 12 mg D1, Dex 8 mg bid D2-4; **Ond 32 mg iv D1 + Dex 12 mg D1, Dex 8 mg D2–4.
Abbreviations:   Aprep, aprepitant; CR, no emesis and no need for rescue antiemetics for 0–120 hours; bid, twice daily; Cas, casopitant; D, day(s); Dex, dexamethasone; HeC, highly 
emetogenic chemotherapy; iv, intravenous; MeC, moderately emetogenic chemotherapy; NA, not available; No ee, no emetic episodes for 0–120 hours; Ond, ondansetron.Therapeutics and Clinical Risk Management 2009:5 381
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IV/PO group experienced improvement of emesis over the 
first 120 hours after MEC. CR (120) was increased to 74% 
versus 59% in the control group, and again improvement 
was maintained in repeat cycles of MEC.45 No significant 
differences in protection from nausea was seen. There were 
no differences in distribution and occurrence of side effects 
among the groups. Neutropenia (with sequelae at 3% inci-
dence were seen in all arms), alopecia, fatigue, leukopenia 
and constipation were the most commonly experienced side-
effects; there were only few reports of injection site reactions, 
and these were seen slightly more frequently in the IV/oral 
group.44,45 It is noteworthy that casopitant administered as 
a single oral dose exhibits similar efficacy as the three-day 
IV/oral dose regimen.
Patients treated with HeC
The phase III, HEC trial was conducted to assess the impact 
of casopitant, when used in combination with ondansetron 
and dexamethasone as compared to ondansetron and dexa-
methasone alone.46,47 810 patients received cisplatin-based 
chemotherapy in a dose of 70 mg/m2 and participated 
in a maximum of six cycles. The study was designed as 
multinational, double-blind and placebo-controlled. The 
control regimen consisted of ondansetron 32 mg IV plus 
dexamethasone 20 mg PO day 1, and dexamethasone 8 mg 
PO twice daily day 2–4 (Table 2). Patients were randomized 
to the control regimen or one of two experimental arms: a 
single dose of casopitant 150 mg PO; a three-day IV/oral 
dose, consisting of casopitant 90 mg IV day 1 and casopitant 
50 mg PO day 2–3. The primary endpoint was complete 
response in the first 120 hours (CR, 120 h) after initiation 
of HEC. In the casopitant 150 mg PO day 1 arm a statisti-
cally significant increase of 20% (86% vs 66% in controls, 
p = 0.0001) in the number of patients with CR (120 h) was 
obtained (Figure 2), and this was maintained over multiple 
cycles. For the HEC regimen casopitant also demonstrated 
efficacy with regard to several secondary endpoints: CR 
(24 h) rates were 95% and 88% for the casopitant 150 mg 
and control groups, respectively (p = 0.0044); and interest-
ingly improvements in no significant nausea (no SN), no 
nausea (NN) and no vomiting (NV) for both the acute and 
delayed phases, were observed as well.46 Casopitant given 
as a three-day IV/oral dose regimen also demonstrated to be 
superior to the control arm. CR (120 h) was achieved in 80% 
of patients (p = 0.0004) and CR (24 h) was 94% in this group 
(p = 0.0165), moreover efficacy was maintained over multiple 
cycles. Again clinically meaningful improvements were 
observed for no SN, NN, or NV.47 Casopitant was generally 
well tolerated. The most frequently reported side effects were 
neutropenia, leukopenia and anemia occurring with similar 
frequency in the experimental- and control arms.46,47
Quality of life
Using the Functional Living Index – Emesis (FLIE) ques-
tionnaire,48 a sub-study addressed quality of life in patients 
receiving HEC and the casopitant antiemetic regimens, as 
described in the phase III, HEC study. The primary end point 
was no impact on daily life (NIDL) defined as a total FLIE 
score 108. In the study 79% of patients in both casopitant 
arms met the NIDL criteria compared to 65% in the control 
arm (p = 0.0005 for single dose, p = 0.0003 for a three-day 
regimen), demonstrating that casopitant, when added to 
standard antiemetic prophylaxis, reduces the impact of 
both nausea and vomiting on daily life activities in patients 
receiving cisplatin-based HEC.49
Conclusion
Casopitant is a novel NK1 receptor antagonist and second in 
the class of antiemetics that acts to antagonise the emeto-
genic effect of substance P. Casopitant has now completed 
phase III trials for prevention of CINV. The drug acts as a 
substrate and a weak-to-moderate inhibitor of CYP3A4.33 
Table 2 Antiemetic regimens in the phase iii, HeC trial46,47 
  Day 1 Day 2 Day 3 Day 4
Control ond  32 mg iv 
dex  20 mg PO 
cas  placebo
 
dex  8 mg bid
 
dex  8 mg bid
 
dex  8 mg bid
Single dose oral ond  32 mg iv 
dex  12 mg PO 
cas  150 mg PO
 
dex  8 mg bid
 
dex  8 mg bid
 
dex  8 mg bid
3 Day iv/oral 
 
ond  32 mg iv 
dex  12 mg PO 
cas  90 mg iv
 
dex  8 mg PO 
cas  50 mg PO
 
dex  8 mg PO 
cas  50 mg PO
 
dex  8 mg PO 
Abbreviations: ond, ondansetron; dex, dexamethasone; cas, casopitant; bid, twice daily; PO, oral; iv,  intravenous.Therapeutics and Clinical Risk Management 2009:5 382
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Hence the early clinical development of casopitant is 
characterized by several phase I studies addressing potential 
drug–drug interactions and toxicity.33–39 Overall, casopitant 
co-administered with ondansetron and dexamethasone, 
warfarin, cyclophosphamide, docetaxel, dolasetron, or 
granisetron caused no toxicity.33–38 Nor the four- to six-fold 
increase in casopitant exposure when co-administered with 
the strong CYP3A4 inhibitor, ketoconazole, caused any safety 
concerns, but should of course be taken into consideration 
if co-administration of these drugs are indicated. Furthermore 
casopitant in this combination did not cause any signifi-
cant impact on QTc interval.38,39 Although casopitant and 
dexamethasone is a safe combination, it is recommended 
that dexamethasone dose should be reduced by 50%, when 
repeat-dose oral dexamethasone is to be co-administered 
with casopitant.33
The primary aim of the two phase II trials’ was finding 
of the appropriate dose of casopitant for phase III studies. In 
the phase II, MEC trial doses of casopitant 50 mg, 100 mg, 
and 150 mg on days 1–3 plus antiemetics as in the control 
arm, were compared to the control arm (ondansetron and 
dexamethasone). All dose regimens proved to be statistically 
significant superior to the control regimen. Furthermore the 
single oral dose of casopitant 150 mg (exploratory arm) 
seemed to possess antiemetic efficacy in the same size as 
the three-day regimens. Similar results were demonstrated 
in the phase II, HEC trial. All doses were well tolerated and 
the most common side-effects experienced by patients in 
the two phase II trials were; nausea, alopecia, neutropenia, 
nausea, anorexia, hiccups, and fatigue.40–43 An intravenous 
formulation of casopitant became available before initiation 
of phase III studies. Consequently, the two large phase III 
trials investigating patients receiving MEC and HEC, respec-
tively, included both oral and intravenous dose regimens of 
casopitant. In both the phase III MEC and HEC studies, all 
casopitant arms (150 mg single oral dose, three-day IV/oral 
and three-day oral) demonstrated statistically significant 
improvement in complete response rates over the first 
120 hours compared to ondansetron plus dexamethasone 
alone.44–47 An important finding was that the single oral dose 
of casopitant 150 mg proved to be as efficient as the three-
day regimens, and all regimens seemed to protect patients 
against emesis in the same order as seen in previous studies 
with aprepitant.6–9
No unexpected side effects have been described in 
phase II–III studies (only abstract publications available). 
Of particular interest is the low degree of neutropenia with 
or without fever. As mentioned, a potential risk of febrile 
neutropenia will be co-administration of casopitant with 
agents like vinorelbine and etoposide, because these are 
metabolized through CYP3A4.
The role of the NK1 receptor antagonists is further 
established with the results of the casopitant studies. Drugs 
in this class of antiemetics are effective in reducing emesis 
induced by both MEC and HEC, and have a significant but 
less pronounced effect against nausea from HEC. Currently 
aprepitant is recommended by the guidelines for preven-
tion of CINV in patients receiving HEC and in patients 
receiving MEC including an anthracycline plus cyclophos-
phamide.50–52 The antiemetic guidelines of the Multinational 
Association of Supportive Care in Cancer (MASCC) and 
those of the European Society for Medical Oncology (ESMO) 
will be updated in a meeting in June 2009. This update 
should take into consideration the results of the phase III 
casopitant trials.
Casopitant has also been investigated for the prevention 
of PONV.53 Future trials should explore other indications 
for casopitant such as patients receiving radiotherapy with 
or without concomitant chemotherapy.
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